Match!
Gerrit Frommeyer
University of Münster
148Publications
18H-index
916Citations
Publications 148
Newest
#1Johanna K. FreundtH-Index: 1
#2Gerrit FrommeyerH-Index: 18
Last.Philipp S. LangeH-Index: 12
view all 11 authors...
Background The development of heart failure is accompanied by complex changes in cardiac electrophysiology and functional properties of cardiomyocytes and fibroblasts. Histone deacetylase (HDAC) inhibitors hold great promise for the pharmaceutical therapy of several malignant diseases. Here, we describe novel effects of the class I HDAC inhibitor Entinostat on electrical and structural remodeling in an in vivo model of pacing induced heart failure.
Source
#1Kevin WillyH-Index: 2
#2Markus BettinH-Index: 5
Last.Gerrit FrommeyerH-Index: 18
view all 10 authors...
Background The subcutaneous ICD (S-ICD™) is an important advance in device therapy for the prevention of sudden cardiac death (SCD). Although current guidelines recommend S-ICD™ use, long-term data are still limited, especially in subgroups. Among several cardiac diseases that prone to SCD, coronary artery disease (CAD) carries several peculiarities that may hamper S-ICD™ therapy in this cohort. CAD can lead to an ischemic cardiomyopathy (ICM) with a reduced left-ventricular ejection fraction (L...
3 CitationsSource
#1Kevin WillyH-Index: 2
#2Florian ReinkeH-Index: 11
Last.Gerrit FrommeyerH-Index: 18
view all 6 authors...
Background The subcutaneous ICD (S-ICD™) is an important advance in device therapy for prevention of sudden cardiac death (SCD). In some patients, decision pro- or contra-ICD implantation is particularly challenging due to inconsistent data on risk of ventricular tachyarrhythmias or sudden cardiac death, rare entities, special medical or family history, or patients’ wishes. Whether decision-making in these borderline cases has been facilitated with the new option of a S-ICD™ is unknown.
Source
#1Gerrit FrommeyerH-Index: 18
Last.Lars EckardtH-Index: 35
view all 4 authors...
Source
#2F CordesH-Index: 2
Last.Lars EckardtH-Index: 35
view all 11 authors...
Source
#1Gerrit Frommeyer (WWU: University of Münster)H-Index: 18
#2Johannes BrachmannH-Index: 40
Last.Lars Eckardt (WWU: University of Münster)H-Index: 35
view all 12 authors...
Background Digitalis glycosides are employed for rate control of atrial fibrillation. Recent studies suggested potential harmful effects of digitalis monotherapy and combination with antiarrhythmic drugs. The aim of the present study was to assess the prevalence and potential impact of digitalis therapy on outcome in patients undergoing catheter ablation of supraventricular arrhythmias.
Source
#1Gerrit FrommeyerH-Index: 18
#2Florian ReinkeH-Index: 11
Last.Lars EckardtH-Index: 35
view all 11 authors...
Source
Source
#1Kevin WillyH-Index: 2
#2Florian ReinkeH-Index: 11
Last.Gerrit FrommeyerH-Index: 18
view all 6 authors...
Source
#1Kevin WillyH-Index: 2
#2Dirk G. DecheringH-Index: 15
Last.Lars EckardtH-Index: 35
view all 10 authors...
Source
12345678910